Physicians' Academy for Cardiovascular Education

BP lowering with endovascular baroreflex amplification in resistant hypertension: the CALM-FIM study

Aug. 29, 2017 - Dr. Wilko Spiering - UMCU

Take home messages of the ESC congress for better hypertension treatment

Aug. 29, 2017 - Dr. Clyde Jancy - Northwestern University, Feinberg University, Chicago, IL, VS

Una nueva era para la prevención cardiovascular: anti-inflamatorios además de la reducción lípidica.

Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Lina Badimon

A new era of CV prevention: Anti-inflammatory drugs on top of lipid lowering

Aug. 29, 2017 - ESC 2017, Barcelona, Spain

MRA treatment early after STEMI may give mortality benefit

Aug. 30, 2017

A new challenge for precision medicine: selecting major contributing risk factors

Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Dopo 23 anni, lo studio CANTOS confermi l'ipotesi sull'infiammazione

Aug. 29, 2017 - ESC 2017, Barcelona, Spain

L’inflammation est critique dans la prévention secondaire des évènements cardiovasculaires

Aug. 28, 2017 - ESC 2017, Barcelona, Spain

The journey from vascular biology to the clinic: reducing inflammation lowers CV risk

Aug. 28, 2017

Well-conducted trial confirms principle that renal denervation can lower blood pressure

Aug. 29, 2017

First time CV reduction is achieved with CETP inhibition

Aug. 29, 2017

Large population study underscores that 'all in moderation' is still good nutrition advice

Aug. 29, 2017

Achieving very low LDL-c levels (<0.5 mmol/L or <20 mg/dL) with PCSK9 inhibition is safe and effective

Aug. 28, 2017

Natural randomisation shows that mode of LDL-lowering determines CV benefit

Aug. 28, 2017

LDL-c still reduced after 1 year with siRNA against PCSK9

Aug. 28, 2017

NSAID ibuprofen increases blood pressure significantly more than other selective COX2 inhibitors

Aug. 28, 2017

Decades of science on the inflammatory hypothesis of atherosclerosis translate into actionable clinical therapeutic to reduce residual CV risk

Aug. 27, 2017

NOAC plus aspirin combination therapy better than aspirin alone to reduce CV events in CAD and PAD

Aug. 27, 2017

Lowering inflammation without affecting LDL-c benefits aggressively treated CV patients

Aug. 27, 2017

BP lowering with endovascular baroreflex amplification in resistant hypertension: the CALM-FIM study

Aug. 29, 2017 - Dr. Wilko Spiering - UMCU
Dr. Wilko Spiering summarises the results of the CALM-FIM study, showing that endovascular baroreflex amplification with MobiusHD device lowers BP in resistant hypertension.

ESC 2017 Dr. Wilko Spiering summarises the results of the CALM-FIM study, showing that endovascular baroreflex amplification with MobiusHD device lowers BP in resistant hypertension.

Take home messages of the ESC congress for better hypertension treatment

Aug. 29, 2017 - Dr. Clyde Jancy - Northwestern University, Feinberg University, Chicago, IL, VS
Clyde Yancy summarises insights of studies presented at the ESC on managment of hypertension and associated CV risk, which can help understanding of how treatment can be improved.

ESC 2017 Clyde Yancy summarises insights of studies presented at the ESC on managment of hypertension and associated CV risk, which can help understanding of how treatment can be improved.

A new era of CV prevention: Anti-inflammatory drugs on top of lipid lowering

Inflammation expert opinions

Aug. 29, 2017 - ESC 2017, Barcelona, Spain
Lina Badimon explains why blocking inflammation may have significant clinical benefit, as inflammation is important in plaque formation.

Inflammation Expert Opinions Lina Badimon explains why blocking inflammation may have significant clinical benefit, as inflammation is important in plaque formation. The results of CANTOS can be the dawn of a new era of CV prevention.

MRA treatment early after STEMI may give mortality benefit

ESC 2017 - Barcelona

Aug. 30, 2017
A patient-level pooled analysis of REMINDER and ALBATROSS data suggests that there may be a mortality benefit of treating STEMI patients with a mineralocorticoid receptor antagonist.

ESC 2017 A patient-level pooled analysis of REMINDER and ALBATROSS data suggests that there may be a mortality benefit of treating STEMI patients with a mineralocorticoid receptor antagonist.

A new challenge for precision medicine: selecting major contributing risk factors

Inflammation expert opinions

Aug. 27, 2017 - ESC 2017, Barcelona, Spain
Erik Stroes summarizes the results from CANTOS and states that for daily clinical practice, it is important to select the major factors contributing to CV risk

Inflammation Expert Opinions Erik Stroes summarizes the results from CANTOS and states that for daily clinical practice, it is important to select the major factors contributing to CV risk

Dopo 23 anni, lo studio CANTOS confermi l'ipotesi sull'infiammazione

Aug. 29, 2017 - ESC 2017, Barcelona, Spain
Filippo Crea riflette su una pubblicazione del 1994, introducendo l’ ipotesi sull’infiammazione e spiega come lo studio CANTOS confermi tale ipotesi.

Inflammation Expert Opinions Filippo Crea riflette su una pubblicazione del 1994, introducendo l’ ipotesi sull’infiammazione e spiega come lo studio CANTOS confermi tale ipotesi. La sfida ora è individuare i pazienti che trarranno beneficio da questo trattamento.

The journey from vascular biology to the clinic: reducing inflammation lowers CV risk

Inflammation expert opinions

Aug. 28, 2017
Paul Ridker and Peter Libby look back at the evolution of their research efforts on the role of inflammation in CV risk, and how they saw their hypothesis confirmed in the CANTOS trial.

Inflammation Expert Opinions Paul Ridker and Peter Libby look back at the evolution of their research efforts on the role of inflammation in CV risk, and how they saw their hypothesis confirmed in the CANTOS trial.

ESC GRAND DEBATE: Aspirin for life

ESC 2017 - Barcelona

Sep. 14, 2017

ESC 2017 One of the ESC Grand Debates revolved around whether or not aspirin should be used for primary and/or secondary CV prevention. Yes, there is a lot of evidence, but how valid is that evidence? Read an impression of this Grand Debate held at ESC 2017.

Well-conducted trial confirms principle that renal denervation can lower blood pressure

ESC 2017 - Barcelona

Aug. 29, 2017
The SPYRAL-HTN study showed encouraging results with renal denervation in a sham-controlled trial. Blood pressure was reduced in patients not requiring medication for their hypertension.

ESC 2017 The SPYRAL-HTN study showed encouraging results with renal denervation in a sham-controlled trial. Blood pressure was reduced in patients not requiring medication for their hypertension.

First time CV reduction is achieved with CETP inhibition

ESC 2017 - Barcelona

Aug. 29, 2017
In the REVEAL study, four years after treatment with the CETP inhibitor anacetrapib in addition to high-dose statin, a 9% reduction of the primary endpoint was seen in CVD patients.

ESC 2017 In the REVEAL study, four years after treatment with the CETP inhibitor anacetrapib in addition to high-dose statin, a 9% reduction of the primary endpoint was seen in CVD patients.

Large population study underscores that 'all in moderation' is still good nutrition advice

Aug. 29, 2017
Data of the large long-term world-wide population study PURE show that 3-4 portions of vegetables and fruit is optimal and fat intake up to 30-35% of calories per day is healthy, irrespective of the type of fat.

ESC 2017 Data of the large long-term world-wide population study PURE show that 3-4 portions of vegetables and fruit is optimal and fat intake up to 30-35% of calories per day is healthy, irrespective of the type of fat.

NOAC-based dual therapy is safer than triple therapy for stent placement in AF patients

ESC 2017 - Barcelona

Aug. 31, 2017 - news

ESC 2017 Fewer major bleedings with dual therapy of dabigatran and platelet inhibitor than with triple therapy with warfarin, platelet inhibitor and aspirin, in AF patients receiving a stent in RE-DUAL PCI..